Large RCT s of CRT 2002 to present

Similar documents
Comparison of clinical trials evaluating cardiac resynchronization therapy in mild to moderate heart failure

Cardiac Devices CRT,ICD: Who is and is not a Candidate? Who Decides

How do I convert my CRT Non Responder into Responder?

BENEFIT OF CRT IN MILDLY SYMPTOMATIC HEART FAILURE RECENT DATA FROM MADIT-CRT AND RAFT

HF and CRT: CRT-P versus CRT-D

Dialysis-Dependent Cardiomyopathy Patients Demonstrate Poor Survival Despite Reverse Remodeling With Cardiac Resynchronization Therapy

The Role of ICD Therapy in Cardiac Resynchronization

Importance of CRT team for optimization of the results: a European point of view

Arthur J. Moss, MD Professor of Medicine/Cardiology University of Rochester Medical Center Rochester, NY. DISCLOSURE INFORMATION Arthur J.

Cardiac resynchronization therapy for heart failure: state of the art

Cardiac Resynchronization Therapy Guidelines and Missing Groups

Devices and Other Non- Pharmacologic Therapy in CHF. Angel R. Leon, MD FACC Division of Cardiology Emory University School of Medicine

Gender and cardiac resynchronization therapy. Chairs: David Heaven & Belinda Green. Gender and Cardiac Resynchronisation Therapy

Cardiac Resynchronization ICD Therapy: What is New?

This is What I do to Improve CRT Response for CRT Non-Responders

Implantable cardioverter-defibrillators and cardiac resynchronization therapy

Provocative Cases: Issues in the Expanding Use of CRT in Treating CHF Patients

Left Ventricular Ejection Fraction >35%

All in the Past? Win K. Shen, MD Mayo Clinic Arizona Controversies and Advances in CV Diseases Cedars-Sinai Heart Institute, MFMER

Device Based Therapy for the Failing Heart: ICD and Cardiac Resynchronization Rx

CRT-P or CRT-D From North Alberta to Nairobi

I NON RESPONDERS ALLA CRT: UN PROBLEMA DI NON SEMPLICE SOLUZIONE

Cardiac Resynchronization Therapy for Heart Failure

MADIT Studies: CRT in the Non-LBBB Patient and Other Findings. Arthur J. Moss, MD

Implantable Cardioverter Defibrillator Therapy in MADIT II Patients with Signs and Symptoms of Heart Failure

Bi-Ventricular pacing after the most recent studies

CRT Vs RV Pacing Benefits

Indications for and Prediction of Successful Responses of CRT for Patients with Heart Failure

How to Approach the Patient with CRT and Recurrent Heart Failure

A Square Peg in a Round Hole: CRT IN PAEDIATRICS AND CONGENITAL HEART DISEASE

14ο Βορειοελλαδικό Καρδιολογικό Συνέδριο ΚΕΒΕ Βηματοδότηση: Νεότερες εξελίξεις Προοπτικές

BSH Annual Autumn Meeting 2017

Do All Patients With An ICD Indication Need A BiV Pacing Device?

Device based CRT optimization: is there a future? Lessons learned from published trials

EBR Systems, Inc. 686 W. Maude Ave., Suite 102 Sunnyvale, CA USA

Cardiac resynchronization therapy for mild-to-moderate heart failure

CRT: whom does it benefit?

WHAT DO ELECTROPHYSIOLOGISTS WANT TO KNOW FROM ECHOCARDIOGRAPHERS BEFORE, DURING&AFTER CARDIAC RESYNCHRONIZATION THERAPY?

Effect of Ventricular Pacing on Myocardial Function. Inha University Hospital Sung-Hee Shin

Name of Policy: Bi-Ventricular Pacemakers (Cardiac Resynchronization Therapy) for the Treatment of Heart Failure

How to Use Echocardiography for. Cardiac Resynchronization Therapy WHY TRY TO IMPROVE PATIENT SELECTION FOR CRT? PROSPECT: CRT Response at 6 Months

Ενδείξεις αμφικοιλιακής βηματοδότησης. Ποιοι ασθενείς με καρδιακή ανεπάρκεια πρέπει να λάβουν αμφικοιλιακό απινιδωτή;

Biventricular Pacemakers (Cardiac Resynchronization Therapy) for the Treatment of Heart Failure

La stimulation biventriculaire (Traitement par Resynchronisation Cardiaque) Indications et Résultats. Daniel Gras, DIU, Paris 2007

Response of Right Ventricular Size to Treatment with Cardiac Resynchronization Therapy and the Risk of Ventricular Tachyarrhythmias in MADIT-CRT

Biventricular Pacemakers (Cardiac Resynchronization Therapy) for the Treatment of Heart Failure

Cardiac Resynchronization Therapy. Michelle Khoo, MD

Is QRS width predictive of the clinical and echocardiographic response to chronic CRT in mildly symptomatic HF patients?

ESC/EHRA. Guidelines on Cardiac Pacing. Panos E. Vardas Professor of Cardiology Heraklion University Hospital Crete, Greece

Primary prevention of SCD with the ICD in Nonischemic Cardiomyopathy

Nonischemic cardiomyopathy, LVEF 31-35%, no prior implant, SR for ANY of the following:

CRT-D or CRT-P: HOW TO CHOOSE THE RIGHT PATIENT?

The Role of Ventricular Electrical Delay to Predict Left Ventricular Remodeling With Cardiac Resynchronization Therapy

ESC Guidelines. ESC Guidelines Update For internal training purpose. European Heart Journal, doi: /eurheart/ehn309

The Influence of Left Ventricular Ejection Fraction on the Effectiveness of Cardiac Resynchronization Therapy

Device Therapy for Heart Failure

CONTAK RENEWAL CLINICAL SUMMARY

It has been shown from meta-analysis of randomized clinical trials that patients with a pre-crt QRS duration (QRSD) >150 ms benefit

Biventricular Pacemakers (Cardiac Resynchronization Therapy) for the Treatment of Heart Failure

Cardiac Resynchronization Therapy: Improving Patient Selection and Outcomes

Heart failure and sudden death

Thoranis Chantrarat MD

Αμφικοιλιακή βηματοδότηση: LBBB ή ευρύ QRS;

Heart Failure Overview. Dr Chris K Y Wong

Need to Know: Implantable Devices. Carolyn Brown RN, MN, CCRN Education Coordinator Emory Healthcare Atlanta, Georgia

Risk Stratification of Sudden Cardiac Death

Role of Ablation of AF and PVCs in the Management of Heart Failure

Biventricular Pacemakers (Cardiac Resynchronization Therapy) for the Treatment of Heart Failure

Dipartimento di Scienze Cardiovascolari Università Campus Bio-Medico di Roma Dott. Vito Calabrese

Upgrade to Resynchronization Therapy. Saeed Oraii MD, Cardiologist Interventional Electrophysiologist Tehran Arrhythmia Clinic May 2016

SCOMPENSO CARDIACO: IL PUNTO DELLA RICERCA

G Lin, R F Rea, S C Hammill, D L Hayes, P A Brady

Resynchronization/Defibrillation

Predictive Power of the Baseline QRS Complex Duration for Clinical Response to Cardiac Resynchronisation Therapy

Cover Page. The handle holds various files of this Leiden University dissertation.

Endpoints When Treating VT/VF in Patients with ICDs Programming Wojciech Zareba, MD, PhD

Nonpharmacologic Treatment of Ventricular Heart Failure

Predictive Power of the Baseline QRS Complex Duration for Clinical Response to Cardiac Resynchronisation Therapy

The road to successful CRT implantation: The role of echo

علم االنسان ما لم يعلم

Rate of Heart failure guideline adherence in a tertiary care center in India after accounting for the therapeutic contraindications.

Author's Accepted Manuscript

Heart Failure Overview. Dr Chris K Y Wong

Journal of the American College of Cardiology Vol. 50, No. 13, by the American College of Cardiology Foundation ISSN /07/$32.

8/8/2011. CARDIAC RESYCHRONIZATION THERAPY for Heart Failure. Case Presentation. Case Presentation

How to Assess Dyssynchrony

Subcutaneous Implantable Cardioverter Defibrillator (S-ICD)

Device therapy in heartfailure Update of the ESC guidelines. Karl Swedberg

JACC: Heart Failure Vol. 1, No. 3, 2013 Ó 2013 by the American College of Cardiology Foundation ISSN /$36.00

Workingman s Guide to CRT Indications: Making Sense of the Various Guidelines

Heart Failure Update. Bibiana Cujec MD May 2015

Live Better Electrically

James H. Baker II, MD St. Thomas Heart Nashville, TN

Prior Authorization Review Panel MCO Policy Submission

Biomarkers and Arrhythmias/Devices Ulrika Birgersdotter-Green, M.D.

The Management of Heart Failure after Biventricular Pacing

Effect of QRS morphology on clinical event reduction with cardiac resynchronization therapy: Meta-analysis of randomized controlled trials

Journal of the American College of Cardiology Vol. 61, No. 14, by the American College of Cardiology Foundation ISSN /$36.

ICD Guidelines: who benefits from an ICD?

Who does not need a primary preventive ICD?

Transcription:

Have We Expanded Our Use of CRT for Heart Failure Patients? Sana M. Al-Khatib, MD, MHS Associate Professor of Medicine Electrophysiology Section- Division of Cardiology Duke University

Potential Conflicts of Interest I receive research funding from the National Heart, Lung and Blood Institute and from the Agency for HealthCare Research and Quality

Cardiac Resynchronization Therapy Large RCT s of CRT 2002 to present MIRACLE (n=453) CONTAK-CD (n=490) COMPANION (n=1520) CARE-HF (n=813) REVERSE (n=610) MADIT-CRT (n=1820) RAFT (n=1798)

Potential Benefits from CRT Survival HF hospitalizations Quality of life Functional status Reduction in MR Improvement in LVEF Reduction in VT/VF Reduction in AF (??)

COmparison of Medical Therapy, Pacing, ANd DefibrillatION in Heart Failure (COMPANION Trial) Bristow MR, et al. NEJM 2004;350:2140-2150

CArdiac REsynchronisation in Heart Failure (CARE-HF) Study (N=813) 1.00 HR 0.63 (95% CI 0.51 to 0.77) nt-free Survival Eve 0.75 0.50 0.25 P < 0.0001 CRT Medical Rx Number at risk CRT Medical Therapy 0.00 0 500 1000 1500 409 323 273 166 68 7 404 292 232 118 48 3 Days Cleland JGF et al. NEJM 2005;352:1539-1549

ACC/AHA 2008 Guidelines for CRT Implantation Class I indication in patients with: LVEF less than or equal to 35% NYHA Class III or ambulatory Class IV heart failure symptoms despite optimal medical therapy QRS duration greater than or equal to 0.12 seconds Sinus rhythm Class IIa indication in patients with all of the above but in atrial fibrillation ill

MADIT-CRT ICM NYHA I/II and NICM NYHA II EF < 0.30; QRS >0.13sec Randomized 1,820 patients ICD only N=731 CRT-D N=1,089 Moss et al. N Engl J Med 2009;361:1329-1338

Resynchronization Defibrillation for Ambulatory Heart Failure Trial (RAFT) NYHA II or III EF < 0.30; intrinsic QRS 0.12sec Randomized 1,798 patients ICD only N=904 CRT-D N= 894 Tang et al. N Engl J Med 2010;363:2385-95

Update to ACC/AHA 2008 Guidelines Tracy CM et al. J Am Coll Cardiol. 2012;60:1297-313.

Update to the ACC/AHA 2008 Guidelines: What Has Not Changed? Class I indication in patients with: LVEF less than or equal to 35% NYHA Class III or ambulatory Class IV heart failure symptoms despite optimal medical therapy QRS duration greater than or equal to 0.12 seconds Sinus rhythm Class IIa indication in patients with all of the above but in atrial fibrillation

Have We Expanded Our Use of CRT for Heart Failure Patients? I do not know! We certainly have new evidence and updated guidelines, but no decisions have been made by CMS regarding reimbursement What are you doing in your practice?

Remember that 30-40% of patients who receive a CRT device do not respond! Define response!!!

Determinants of Response to CRT Patient characteristics: LBBB vs. non-lbbb (a word about RBBB) Non-ischemic CMY vs. ischemic CMY Women vs. Men Older patients t Patients with multiple comorbidities Location of the CS lead Programming of the device

Effects of CRT-D by QRS Morphology in MADIT-CRT Non- LBBB IVCD, 306, 17% 534, 30% RBBB, 228, 13% LBBB 1281 LBBB, 1281, 70% Zareba et al. Circulation 2011;123:1061-1072

Cumulative Probability of Heart Failure Events or Death by Treatment in Patients with LBBB and Non-LBBB HR=0.47 p<0.001 HR=1.24 p<0.257 LBBB Non-LBBB Zareba et al. Circulation 2011;123:1061-1072

Cumulative Probability of Heart Failure Events or Death by Treatment in Patients with LBBB QRS in MADIT-CRT HR=0.47 p<0.001 16% Zareba et al. Circulation 2011;123:1061-1072

Response to CRT: Patient Selection Ischemic versus Non-Ischemic Adelstein et al. Eur Heart J 2011;32:93-103

From: Cardiac Resynchronization Therapy Is More Effective in Women Than in Men: Title and subtitle BreakThe MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy) Trial J Am Coll Cardiol. 2011;57(7):813-820. doi:10.1016/j.jacc.2010.06.061 Figure Legend: Kaplan-Meier Estimates of Cumulative Probability of Heart Failure or Death Stratified by Sex and ICD or CRT-D Therapy The 4 curves reflect the probability of heart failure or death, whichever comes first, over time in women and men having the device therapy implanted cardioverter-defibrillator (ICD) or cardiac resynchronization therapy with defibrillator (CRT-D) to which they were randomized. Women randomly assigned to CRT-D therapy (blue line) had the best result. The purple line indicates female ICD therapy; the black line indicates male ICD therapy; and the red line indicates male CRT-D therapy. Date of download: Copyright The American College of Cardiology. 1/23/2013 All rights reserved.

From: Cardiac Resynchronization Therapy Is More Effective in Women Than in Men: Title and subtitle BreakThe MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy) Trial J Am Coll Cardiol. 2011;57(7):813-820. doi:10.1016/j.jacc.2010.06.061 Figure Legend: Kaplan-Meier Estimates of the Cumulative Probability of Death in Women and Men by Device Therapy (A) Women had a significantly lower probability of death over time with CRT-D (red line) than with ICD (black line). (B) Men had similar probability of death over time with CRT-D therapy (red line) or with ICD therapy (black line). Abbreviations as in Figure 1. Date of download: 1/23/2013 Copyright The American College of Cardiology. All rights reserved.

Determinants of Response to CRT Patient characteristics: LBBB vs. non-lbbb (a word about RBBB) Non-ischemic CMY vs. ischemic CMY Women vs. Men Older patients t Patients with multiple comorbidities Location of the CS lead Programming of the device

LV Lead Location MADIT-CRT Singh, J et al. Circulation. 2011;123:1159-1166

LV Lead Location Echocardiography guided LV lead placement targeting the site of latest LV mechanical activation Avoiding scar

Device Programming Do everything you can to achieve 100% biv-pacing. Make sure you have enough safety margin for the pacing output of the LV lead Optimizing the AV interval and the VV interval Optimizing the AV interval and the VV interval (random)

Gaps in Knowledge What is the best measure of dyssynchrony? Many echo tests have been proposed, but none has been proven to be accurate in distinguishing responders from non-responders These tests lack sensitivity, specificity, and reproducibility Al-Khatib

Predictors of Response to CRT (PROSPECT) N= 426 patients Studied 12 echocardiographic methods for their ability to predict response All methods lacked sensitivity and specificity to affect clinical decisions These methods should not be used routinely in evaluating a patient for CRT Other methods are under investigation (eg, strain measurements, 3-dimensional imaging, scar location) that may be able to distinguish responders from non-responders with more accuracy However, before they can be recommended for general use, their applicability should be tested in a multi-center setting Al-Khatib Chung ES et al. Circulation 2008;117;2608-16

Question # 1 Which of the following patients is least likely to benefit from CRT? A 64 yo woman with NYHA class III, LVEF of 20%, non-ischemic CMY, QRS width of 150 ms with LBBB morphology A 50 yo man with NYHA class III, ischemic CMY with an EF of 25%, QRS width of 140 and LBBB A78 yo man with NYHA class II, ischemic i cardiomhyiopathy with an LVEF of 10% and QRS width of 130 ms with non-lbbb

Question # 2 Which of the following is true: CRT is a Class I indication in patients with NYHA class I sxs, LVEF < 30%, QRS of > 150 ms with LBBB and ischemic CMY CRT should be offered to all patients regardless of their burden of comorbidities or their life expectancy CRT has been shown to improve survival and reduce heart failure hospitalizations in patients with a QRS width of 110 ms The RCT that convincingly showed improved survival from CRT alone was CARE-HF

Conclusions Is the following statement true or false? Echocardiography-guided guided LV lead placement targeting the site of latest LV mechanical activation has been shown to improve patient outcomes

Conclusions CRT has been shown to improve survival and reduce heart failure hospitalizations in patients with an LVEF 35%, a wide QRS complex, NYHA class II, III and ambulatory class IV symptoms despite optimal medical therapy Certain groups of patients are more likely to benefit from CRT than others Uncertainties remain regarding the best measure of dyssynchrony and the best method for optimization Imaging-guided guided LV lead placement will become more widespread Al-Khatib